(Q36758574)

16 August 2017

1 reference

title

Problems and emerging approaches in HIV/AIDS vaccine development (English)

1 reference

16 August 2017

1 reference

Flavia Ferrantelli

3

0 references

Fabrizio Ensoli

Fabrizio Ensoli

8

0 references

Antonella Caputo

Antonella Caputo

6

0 references

Riccardo Gavioli

Riccardo Gavioli

7

0 references

Barbara Ensoli

Barbara Ensoli

11

0 references

Marjorie Robert-Guroff

9

Marjorie Robert-Guroff

1 reference

16 August 2017

Fausto Titti

1

1 reference

16 August 2017

Aurelio Cafaro

2

1 reference

16 August 2017

Antonella Tripiciano

4

1 reference

16 August 2017

Sonia Moretti

5

1 reference

16 August 2017

Susan Barnett

10

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

Expert Opinion on Emerging Drugs

16 August 2017

published in

1 reference

16 August 2017

volume

12

1 reference

16 August 2017

issue

1

1 reference

16 August 2017

page(s)

23-48

1 reference

Mouse models for HIV-1 infection

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Rodent models for HIV-1 infection and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Development of a Moloney murine leukemia virus-based pseudotype anti-HIV assay suitable for accurate and rapid evaluation of HIV entry inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

A mouse model for study of systemic HIV-1 infection, antiviral immune responses, and neuroinvasiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Induction of HIV-1-specific immunity after vaccination with apoptotic HIV-1/murine leukemia virus-infected cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Rapid CD4(+) T-cell loss induced by human immunodeficiency virus type 1(NC) in uninfected and previously infected chimpanzees

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Comparative evaluation of simian, simian-human, and human immunodeficiency virus infections in the pigtail macaque (Macaca nemestrina) model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Baboons as an animal model for human immunodeficiency virus pathogenesis and vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Simian immunodeficiency virus SIVagm.sab infection of Caribbean African green monkeys: a new model for the study of SIV pathogenesis in natural hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

HIV-1 fitness and disease progression: insights from the SIV-macaque model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Repeated low-dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high-dose challenge: a model for the evaluation of vaccine efficacy in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Long-lasting protection by live attenuated simian immunodeficiency virus in cynomolgus monkeys: no detection of reactivation after stimulation with a recall antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Influence of glycosylation on the efficacy of an Env-based vaccine against simian immunodeficiency virus SIVmac239 in a macaque AIDS model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

In vitro immunomodulation and in vivo immunotherapy of retrovirus-induced immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Quantifying the uncertainty in forecasts of anthropogenic climate change

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Perils at mucosal front lines for HIV and SIV and their hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Viral piracy: HIV-1 targets dendritic cells for transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Induction of optimal immune responses against human immunodeficiency virus at mucosal portals of entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Chemokines and the tissue-specific migration of lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Immunological recovery and antiretroviral therapy in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Betulinic acid derivatives as HIV-1 antivirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Advances in HIV-1 entry inhibitors: strategies to interfere with receptor and coreceptor engagement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Transient early post‐inoculation anti‐retroviral treatment facilitates controlled infection with sparing of CD4+ T cells in gut‐associated lymphoid tissues in SIVmac239‐infected rhesus macaques, but not resistance to rechallenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Requirement of diverse T-helper responses elicited by HIV vaccines: induction of highly targeted humoral and CTL responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Effector and memory T-cell differentiation: implications for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine in macaques: effect of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus-HIV-1 chimeric virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Antibody vs. HIV in a clash of evolutionary titans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Purification, Characterization, and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from SF162, an R5-Tropic Human Immunodeficiency Virus Type 1 Isolate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Vaccination with Rev and Tat against AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

A novel chimeric Rev, Tat, and Nef (Retanef) antigen as a component of an SIV/HIV vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat Oyi vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Evolution of CD8+ T cell immunity and viral escape following acute HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Recent advances in the development of HIV-1 Tat-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Immunobiology of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Dendritic cells in innate immune responses against HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Dendritic cells: specialized and regulated antigen processing machines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Therapeutic dendritic-cell vaccine for simian AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Successful tumor eradication was achieved by collaboration of augmented cytotoxic activity and anti-angiogenic effects following therapeutic vaccines containing helper-activating analog-loaded dendritic cells and tumor antigen DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Microparticle-based technologies for vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Core-shell microspheres by dispersion polymerization as promising delivery systems for proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

HIV vaccine design and the neutralizing antibody problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies--implications for acquired immunodeficiency syndrome vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Immunoprophylaxis to prevent mother-to-child transmission of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

The multiple functions of HIV-1 Tat: proliferation versus apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Specific interaction of Tat with the human but not rodent P-TEFb complex mediates the species-specific Tat activation of HIV-1 transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Multiple effects of HIV-1 trans-activator protein on the pathogenesis of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Human immunodeficiency virus type 1 Tat protein modulates cell cycle and apoptosis in Epstein-Barr virus-immortalized B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Dynamic Nef and Nef dynamics: how structure could explain the complex activities of this small HIV protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Live and let die: Nef functions beyond HIV replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

HIV-1 Nef-induced FasL induction and bystander killing requires p38 MAPK activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Induction of fas ligand expression by an acutely lethal simian immunodeficiency virus, SIVsmmPBj14.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

HIV-1 Nef enhances both membrane expression and virion incorporation of Env products. A model for the Nef-dependent increase of HIV-1 infectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

A nucleolar localizing Rev binding element inhibits HIV replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Rev activity determines sensitivity of HIV-1-infected primary T cells to CTL killing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Intracellular HIV-1 Tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

HIV-1 Nef induces dendritic cell differentiation: a possible mechanism of uninfected CD4(+) T cell activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Live attenuated simian immunodeficiency virus prevents super-infection by cloned SIVmac251 in cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Mucosal delivery of vaccine antigens and its advantages in pediatrics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

The HIV-1 matrix protein p17 can be efficiently delivered by intranasal route in mice using the TLR 2/6 agonist MALP-2 as mucosal adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

ISCOM-based vaccines: the second decade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Ginseng and Salviae herbs play a role as immune activators and modulate immune responses during influenza virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Mucosal AIDS vaccines: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Strategies for designing and optimizing new generation vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

HIV and the chemokine system: 10 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Delivery of the HIV-1 Tat protein to dendritic cells by the CyaA vector induces specific Th1 responses and high affinity neutralizing antibodies in non human primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

A review of vaccine research and development: the human immunodeficiency virus (HIV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Immunization with low doses of HIV-1 tat DNA delivered by novel cationic block copolymers induces CTL responses against Tat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Medicine. The need for a global HIV vaccine enterprise

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

The impact of human allelic variation on HIV-1 disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

The role of a mutant CCR5 allele in HIV-1 transmission and disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Changes in soluble factor-mediated CD8+ cell-derived antiviral activity in cynomolgus macaques infected with simian immunodeficiency virus SIVmac251: relationship to biological markers of progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

The search for the CD8+ cell anti-HIV factor (CAF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Innate cellular defenses of APOBEC3 cytidine deaminases and viral counter-defenses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Natural killer cells and HIV-1 disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

HIV-1 induces cytotoxic T lymphocytes in the cervix of infected women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: implications for HIV primary infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

The evolutionary adaptation of HIV-1 to specific immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Evasion of cytotoxic T lymphocyte (CTL) responses by nef-dependent induction of Fas ligand (CD95L) expression on simian immunodeficiency virus-infected cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Effect of vaccination with recombinant modified vaccinia virus Ankara expressing structural and regulatory genes of SIV(macJ5) on the kinetics of SIV replication in cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Protection from immunodeficiency virus challenges in rhesus macaques by multicomponent DNA immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal simian immunodeficiency virus challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Minimization of chronic plasma viremia in rhesus macaques immunized with synthetic HIV-1 Tat peptides and infected with a chimeric simian/human immunodeficiency virus (SHIV33).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag c

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Comparison of the efficacy of early versus late viral proteins in vaccination against SIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Therapeutic Immunization with Dendritic Cells Loaded with Heat‐Inactivated Autologous HIV‐1 in Patients with Chronic HIV‐1 Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

HIV-1 Nef-Induced Upregulation of DC-SIGN in Dendritic Cells Promotes Lymphocyte Clustering and Viral Spread

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Evaluation in Rhesus Macaques of Tat and Rev-Targeted Immunization as a Preventive Vaccine against Mucosal Challenge with SHIV-BX08

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Mucosal and systemic HIV-1-specific immunity in HIV-1-exposed but uninfected heterosexual men

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

Failure to eradicate HIV despite fully successful HAART initiated in the first days of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

HIV type 1 Tat protein enhances activation-but not Fas (CD95)-induced peripheral blood T cell apoptosis in healthy individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.1.23

21 January 2018

Identifiers

DOI

10.1517/14728214.12.1.23

1 reference

16 August 2017

1 reference